ATE534415T1
(de)
|
2005-12-13 |
2011-12-15 |
Harvard College |
Gerüste zur zelltransplantation
|
PL2624873T3
(pl)
|
2010-10-06 |
2020-12-14 |
President And Fellows Of Harvard College |
Nadające się do wstrzykiwania hydrożele tworzące pory do terapii komórkowych opartych na materiałach
|
LT2838515T
(lt)
|
2012-04-16 |
2020-03-10 |
President And Fellows Of Harvard College |
Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
|
CA2876150A1
(en)
|
2012-06-08 |
2013-12-12 |
The Johns Hopkins University |
Compostions and methods for cancer immunotherapy
|
SG10201704611WA
(en)
|
2012-12-13 |
2017-07-28 |
Aduro Biotech Inc |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
AP2015008746A0
(en)
|
2013-04-29 |
2015-09-30 |
Univ Bonn |
Compositions and methods for altering second messenger signaling
|
US20140329889A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
US9549944B2
(en)
*
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
CN105228450B
(zh)
|
2013-05-18 |
2019-01-18 |
艾杜罗生物科技公司 |
用于活化“干扰素基因刺激因子”-依赖性信号传导的组合物和方法
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
EP3071209A4
(en)
*
|
2013-11-19 |
2017-08-16 |
The University of Chicago |
Use of sting agonist as cancer treatment
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015168379A2
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
AU2015270640B2
(en)
|
2014-06-04 |
2017-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic di-nucleotides as modulators of STING
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
JP6762030B2
(ja)
*
|
2014-11-20 |
2020-09-30 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途
|
PL3233882T3
(pl)
*
|
2014-12-16 |
2020-04-30 |
Kayla Therapeutics |
Fluorowane cykliczne dinukleotydy do indukcji cytokin
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2016123573A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
US10130663B2
(en)
|
2015-02-11 |
2018-11-20 |
The John Hopkins University |
Bacteria over-expressing c-di-AMP and therapeutic methods
|
EP3268035A4
(en)
|
2015-03-10 |
2018-10-31 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
WO2016164705A1
(en)
|
2015-04-10 |
2016-10-13 |
Omar Abdel-Rahman Ali |
Immune cell trapping devices and methods for making and using the same
|
EP3326641B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
US20180222982A1
(en)
*
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
CN106692967A
(zh)
*
|
2015-08-12 |
2017-05-24 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合PD1的抗体(Nivolumab)在制备抗肿瘤药物中的应用
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
CA2995365C
(en)
|
2015-08-13 |
2021-10-12 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
CN106540255A
(zh)
*
|
2015-09-18 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
|
EP3368072A4
(en)
|
2015-10-28 |
2019-07-03 |
Aduro BioTech, Inc. |
COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
CR20180286A
(es)
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
BR112018012374A2
(pt)
|
2015-12-16 |
2018-12-04 |
Gritstone Oncology, Inc. |
identificação, fabricação e uso de neoantígeno
|
US20180369268A1
(en)
*
|
2015-12-16 |
2018-12-27 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
|
BR112018012138A2
(pt)
|
2015-12-17 |
2018-12-04 |
Novartis Ag |
moléculas de anticorpo para pd-1 e usos das mesmas
|
AU2017208133B2
(en)
|
2016-01-11 |
2023-12-21 |
Universitat Zurich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
EA036421B1
(ru)
|
2016-01-11 |
2020-11-09 |
Иннэйт Тьюмор Иммьюнити, Инк. |
Соединения и композиции для лечения состояний, ассоциированных с активностью sting
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
CN106544319A
(zh)
*
|
2016-01-24 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法
|
WO2017136837A1
(en)
|
2016-02-06 |
2017-08-10 |
President And Fellows Of Harvard College |
Recapitulating the hematopoietic niche to reconstitute immunity
|
JP6980198B2
(ja)
|
2016-03-18 |
2021-12-15 |
イミューン センサー リミテッド ライアビリティ カンパニー |
環状ジヌクレオチド化合物および使用方法
|
CN106540256A
(zh)
*
|
2016-03-27 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
|
ES2781474T3
(es)
|
2016-04-07 |
2020-09-02 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas
|
HRP20220936T1
(hr)
|
2016-04-07 |
2022-10-28 |
Glaxosmithkline Intellectual Property Development Limited |
Heterociklički amidi korisni kao modulatori proteina
|
EP3445761A1
(en)
|
2016-04-19 |
2019-02-27 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
US10696985B1
(en)
|
2016-06-06 |
2020-06-30 |
Vanderbilt University |
Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
|
EP3507367A4
(en)
*
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
EP3481402A4
(en)
*
|
2016-07-06 |
2020-01-22 |
Sperovie Biosciences, Inc. |
CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
|
WO2018009652A1
(en)
*
|
2016-07-06 |
2018-01-11 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
CN115305229A
(zh)
|
2016-07-13 |
2022-11-08 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
EP3497119A1
(en)
|
2016-08-09 |
2019-06-19 |
Aarhus Universitet |
Modulation of ifi16 and sting activity
|
EP3922279A1
(en)
|
2016-08-30 |
2021-12-15 |
Dana Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
US11052149B2
(en)
|
2016-09-19 |
2021-07-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for inducing an immune response
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
SG10202008647TA
(en)
|
2016-10-04 |
2020-10-29 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
WO2018065360A1
(de)
|
2016-10-07 |
2018-04-12 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
EP3525817A4
(en)
*
|
2016-10-11 |
2020-09-16 |
The Governors of the University of Alberta |
IMMUNOGENIC HEPATITIS C VIRUS COMPOSITIONS WITH A CYCLIC DINUCLEOTIDE OR ARCHAEOSOME AS ADJUVANS AND METHOD OF USE THEREOF
|
JOP20170188A1
(ar)
*
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
JP2018090562A
(ja)
*
|
2016-12-01 |
2018-06-14 |
武田薬品工業株式会社 |
環状ジヌクレオチド
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
JP2020511420A
(ja)
*
|
2016-12-20 |
2020-04-16 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がんの処置のためのpd−1アンタゴニストと環状ジヌクレオチドstingアゴニストとの組み合わせ
|
WO2018118665A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
EP3573717B1
(en)
|
2017-01-27 |
2021-07-28 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
WO2018156625A1
(en)
|
2017-02-21 |
2018-08-30 |
Board Of Regents,The University Of Texas System |
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
|
CN106727331B
(zh)
*
|
2017-03-13 |
2022-02-01 |
杭州星鳌生物科技有限公司 |
免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
|
JP2020514378A
(ja)
|
2017-03-20 |
2020-05-21 |
ジェノセア バイオサイエンシーズ, インコーポレイテッド |
処置方法
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
CA3058134A1
(en)
|
2017-04-13 |
2018-10-18 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
NZ758119A
(en)
|
2017-04-14 |
2024-03-22 |
Tallac Therapeutics Inc |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
AR113224A1
(es)
*
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
WO2018208667A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
CN108853144A
(zh)
*
|
2017-05-16 |
2018-11-23 |
科济生物医药(上海)有限公司 |
Toll样受体激动剂与免疫效应细胞的联用
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
JP7433910B2
(ja)
|
2017-06-22 |
2024-02-20 |
ノバルティス アーゲー |
Cd73に対する抗体分子及びその使用
|
WO2019014402A1
(en)
|
2017-07-14 |
2019-01-17 |
Innate Tumor Immunity, Inc. |
MODULATORS OF NLRP3
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がん治療のためのベンゾ[b]チオフェンSTINGアゴニスト
|
CA3071537A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
Combinations of pd-1 antagonists and benzo[b]thiophene sting agonists for cancer treatment
|
WO2019043634A2
(en)
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
KR102651946B1
(ko)
*
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
EP3676279B1
(en)
*
|
2017-08-31 |
2021-12-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
CA3074232A1
(en)
|
2017-08-31 |
2019-03-07 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
IL311010A
(en)
|
2017-09-08 |
2024-04-01 |
Univ Leland Stanford Junior |
ENPP1 inhibitors and their use for cancer treatment
|
US11584774B2
(en)
|
2017-09-11 |
2023-02-21 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
JP7291130B2
(ja)
|
2017-10-05 |
2023-06-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
インターフェロン遺伝子の刺激物質(sting)の調節物質
|
EP3694532A4
(en)
|
2017-10-10 |
2021-07-14 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
JP7195317B2
(ja)
|
2017-11-10 |
2022-12-23 |
武田薬品工業株式会社 |
Sting調節剤化合物、ならびに製造及び使用する方法
|
EA038805B1
(ru)
*
|
2017-11-21 |
2021-10-21 |
Такеда Фармасьютикал Компани Лимитед |
Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
|
JP2021503897A
(ja)
|
2017-11-22 |
2021-02-15 |
グリットストーン オンコロジー インコーポレイテッド |
新生抗原のためのジャンクションエピトープ提示の低減
|
US11633473B2
(en)
|
2017-11-27 |
2023-04-25 |
Children's Medical Center Corporation |
Stimulator of Interferon Genes (STING) ligands and uses thereof
|
JP7317014B2
(ja)
*
|
2017-12-15 |
2023-07-28 |
ヤンセン バイオテツク,インコーポレーテツド |
Stingアゴニストとしての環状ジヌクレオチド
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
JP7230035B2
(ja)
*
|
2018-01-04 |
2023-02-28 |
アカデミア シニカ |
治療を強化するための細胞会合免疫アジュバントならびに同アジュバントを含むキットおよび処方物
|
CN111655281A
(zh)
*
|
2018-01-26 |
2020-09-11 |
加利福尼亚大学董事会 |
用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送
|
SG11202007240QA
(en)
|
2018-02-02 |
2020-08-28 |
Novartis Ag |
Combination of sting agonist and il-15/il15-ra for the treatment of cancer
|
WO2019154844A1
(en)
*
|
2018-02-06 |
2019-08-15 |
Aarhus Universitet |
Modulation of p62 and sting activity
|
TW202003023A
(zh)
|
2018-03-12 |
2020-01-16 |
美商詹森藥物公司 |
針對***之疫苗
|
CN110272462B
(zh)
*
|
2018-03-15 |
2023-03-10 |
南开大学 |
制备化合物的方法
|
SG11202008636YA
(en)
|
2018-03-23 |
2020-10-29 |
Codiak Biosciences Inc |
Extracellular vesicles comprising sting-agonist
|
JP2021519270A
(ja)
|
2018-03-27 |
2021-08-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
2−アザ−ヒポキサンチンまたは6h−ピラゾロ[1,5−d][1,2,4]トリアジン−7−オンをstingアゴニストとして含む環式ジヌクレオチド化合物
|
US20210024567A1
(en)
|
2018-03-27 |
2021-01-28 |
Boehringer Ingelheim International Gmbh |
Modified cyclic dinucleotide compounds
|
AU2019248545B2
(en)
|
2018-04-03 |
2022-08-11 |
Merck Sharp & Dohme Llc |
Benzothiophenes and related compounds as sting agonists
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TWI833744B
(zh)
*
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
US12037344B2
(en)
|
2018-04-25 |
2024-07-16 |
Innate Tumor Immunity, Inc |
NLRP3 modulators
|
CN108310378A
(zh)
*
|
2018-04-28 |
2018-07-24 |
杭州星鳌生物科技有限公司 |
一类新型免疫联体抗肿瘤创新药物的制备及其应用
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
MX2020012964A
(es)
|
2018-06-01 |
2021-02-16 |
Eisai R&D Man Co Ltd |
Metodos para el tratamiento de cancer de vejiga.
|
WO2019246450A1
(en)
*
|
2018-06-20 |
2019-12-26 |
Yale University |
Rig-i agonists and treatments using same
|
JP2021529833A
(ja)
|
2018-07-03 |
2021-11-04 |
アイエフエム デュー インコーポレイテッド |
Sting活性に関連する状態を治療するための化合物および組成物
|
EP3818044A1
(en)
|
2018-07-03 |
2021-05-12 |
IFM Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
SG11202100023XA
(en)
*
|
2018-07-11 |
2021-01-28 |
Actym Therapeutics Inc |
Engineered immunostimulatory bacterial strains and uses thereof
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
KR20210045430A
(ko)
|
2018-08-16 |
2021-04-26 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
KR20210045352A
(ko)
|
2018-08-16 |
2021-04-26 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
화합물의 염 및 이의 결정
|
CN112888677A
(zh)
|
2018-08-16 |
2021-06-01 |
先天肿瘤免疫公司 |
被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
|
EP3841112A1
(en)
|
2018-08-24 |
2021-06-30 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
CA3111397A1
(en)
|
2018-09-06 |
2020-03-12 |
Daiichi Sankyo Company, Limited |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
WO2020059895A1
(ko)
*
|
2018-09-17 |
2020-03-26 |
주식회사 큐라티스 |
스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
|
CA3113425A1
(en)
|
2018-09-21 |
2020-03-26 |
Shanghai De Novo Pharmatech Co., Ltd. |
Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
WO2020092127A1
(en)
|
2018-10-29 |
2020-05-07 |
Venenum Biodesign, LLC |
Novel sting agonists
|
US20220412979A1
(en)
|
2018-10-29 |
2022-12-29 |
Genocea Biosciences, Inc. |
Treatment methods
|
US20220008346A1
(en)
|
2018-10-30 |
2022-01-13 |
Vanderbilt University |
Graft copolymers, methods of forming graft copolymers, and methods of use thereof
|
US20210170043A1
(en)
|
2018-10-31 |
2021-06-10 |
Novartis Ag |
Dc-sign antibody conjugates comprising sting agonists
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
US20220024964A1
(en)
*
|
2018-12-07 |
2022-01-27 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
US20220033431A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
US20220033435A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
WO2020143740A1
(zh)
*
|
2019-01-10 |
2020-07-16 |
南开大学 |
环二核苷酸前药分子及其制备方法和应用
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
EP3911417B1
(en)
|
2019-01-14 |
2022-10-26 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators , for use in the treatment of cancer
|
JP7373571B2
(ja)
|
2019-01-14 |
2023-11-02 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がん治療に用いるためのnlrp3モジュレーターとしての置換キナゾリン
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
TW202043198A
(zh)
|
2019-01-17 |
2020-12-01 |
美商Ifm Due有限公司 |
用於治療與sting活性相關之病況的化合物及組合物
|
US10998091B2
(en)
|
2019-02-07 |
2021-05-04 |
Sandeep Patil |
Systems for monitoring compliance with a patch dosage regimen and methods of using the same
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
CN113543851A
(zh)
*
|
2019-03-07 |
2021-10-22 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
AU2020231115A1
(en)
*
|
2019-03-07 |
2021-08-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
KR102574882B1
(ko)
|
2019-03-18 |
2023-09-04 |
얀센 파마슈티칼즈, 인코포레이티드 |
대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
|
SG11202110301TA
(en)
|
2019-03-18 |
2021-10-28 |
Janssen Pharmaceuticals Inc |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
US20220168415A1
(en)
|
2019-03-21 |
2022-06-02 |
Codiak Biosciences, Inc. |
Extracellular vesicles for vaccine delivery
|
CA3133314A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Extracellular vesicle conjugates and uses thereof
|
US20220387906A1
(en)
|
2019-03-21 |
2022-12-08 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
WO2020227421A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as sting modulators
|
US20220409734A1
(en)
|
2019-05-10 |
2022-12-29 |
Yutaka Nishimoto |
Antibody drug conjugates
|
JP2022535743A
(ja)
|
2019-05-29 |
2022-08-10 |
アイエフエム デュー インコーポレイテッド |
Sting活性に関連する状態を治療するための化合物および組成物
|
EP3994158A1
(en)
|
2019-07-03 |
2022-05-11 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
US20220259254A1
(en)
|
2019-07-05 |
2022-08-18 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021026009A1
(en)
|
2019-08-02 |
2021-02-11 |
Mersana Therapeutics, Inc. |
Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
|
JP2022544549A
(ja)
|
2019-08-12 |
2022-10-19 |
ピュリノミア バイオテック, インコーポレイテッド |
Cd39発現細胞のadcc標的化を介してt細胞媒介性免疫応答を促進及び増強するための方法及び組成物
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
EP3785719A1
(en)
*
|
2019-08-28 |
2021-03-03 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
New use of cyclic dinucleotides
|
AU2020355240A1
(en)
|
2019-09-25 |
2022-04-21 |
Lonza Sales Ag |
Extracellular vesicle compositions
|
US20230103726A1
(en)
|
2019-09-25 |
2023-04-06 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
EP4034150A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
|
US20220362368A1
(en)
|
2019-10-02 |
2022-11-17 |
Janssen Vaccines & Prevention B.V. |
Staphylococcus peptides and methods of use
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
EP4087842A1
(en)
|
2020-01-10 |
2022-11-16 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
BR112022013720A2
(pt)
|
2020-01-16 |
2022-10-11 |
Janssen Pharmaceuticals Inc |
Mutante fimh, composições com o mesmo e seu uso
|
KR20220162130A
(ko)
|
2020-02-28 |
2022-12-07 |
탈락 테라퓨틱스, 인크. |
트랜스글루타미나제-매개된 접합
|
JPWO2021177438A1
(es)
|
2020-03-06 |
2021-09-10 |
|
|
EP4117717A1
(en)
|
2020-03-13 |
2023-01-18 |
Codiak BioSciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
JP2023518414A
(ja)
|
2020-03-20 |
2023-05-01 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
治療のための細胞外小胞
|
KR20220167275A
(ko)
|
2020-04-10 |
2022-12-20 |
오노 야꾸힝 고교 가부시키가이샤 |
암 치료 방법
|
US11857618B2
(en)
|
2020-04-17 |
2024-01-02 |
Emory University |
Boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
|
CN115835856A
(zh)
|
2020-05-13 |
2023-03-21 |
麻省理工学院 |
聚合物微装置的组合物以及其在癌症免疫疗法中的用途
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
WO2022032191A1
(en)
|
2020-08-07 |
2022-02-10 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
TW202227479A
(zh)
|
2020-09-02 |
2022-07-16 |
日商第一三共股份有限公司 |
新穎內-β-N-乙醯葡萄糖胺苷酶
|
EP4210707A1
(en)
|
2020-09-08 |
2023-07-19 |
The Board Of Regents Of The University Of Texas System |
Polyvalent sting activating compositions and uses thereof
|
UY39428A
(es)
|
2020-09-17 |
2022-03-31 |
Janssen Pharmaceuticals Inc |
Composiciones de vacunas multivalentes y usos de las mismas
|
WO2022066898A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
CA3193107A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
US20220111028A1
(en)
|
2020-10-14 |
2022-04-14 |
Boehringer Ingelheim International Gmbh |
Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
|
EP3984535A1
(en)
|
2020-10-16 |
2022-04-20 |
Albert-Ludwigs-Universität Freiburg |
Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
|
KR20230107586A
(ko)
|
2020-10-20 |
2023-07-17 |
타이리간드 바이오사이언스 (상하이) 리미티드 |
다기능성 사이클릭 디뉴클레오티드 및 이의 용도
|
KR20230141754A
(ko)
|
2020-10-30 |
2023-10-10 |
아박타 라이프 사이언시스 리미티드 |
Fap-활성화 혈청 반감기 연장된 치료 접합체
|
CA3197167A1
(en)
|
2020-11-09 |
2022-05-12 |
He Xu |
Antibody drug conjugates
|
US20220211883A1
(en)
|
2020-12-17 |
2022-07-07 |
Trustees Of Tufts College |
Fap-activated radiotheranostics and uses related thereto
|
CA3207841A1
(en)
|
2021-01-12 |
2022-07-21 |
Janssen Pharmaceuticals, Inc |
Fimh mutants, compositions therewith and use thereof
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
CA3215752A1
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Pharmaceuticals, Inc. |
Production of e. coli o18 bioconjugates
|
JP2024514707A
(ja)
|
2021-04-20 |
2024-04-02 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
US20220313724A1
(en)
*
|
2021-05-17 |
2022-10-06 |
Highlight Therapeutics, S.L. |
Compositions for intratumoral administration and related methods
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
CN114106140A
(zh)
*
|
2021-11-23 |
2022-03-01 |
哈尔滨医科大学附属肿瘤医院 |
一种表达特定sting异构体、细胞系、制备方法、用途
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|